GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Medicine

More

  • July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...

  • Gilead posts huge beat on earnings and revenue Tuesday, 28 Jul 2015 | 5:28 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.

  • FDA approves stomach-filling balloon for weight loss Tuesday, 28 Jul 2015 | 5:24 PM ET

    Patients are sedated during the procedure, which takes less than 30 minutes, according to an FDA release. The FDA previously approved another balloon device for weight loss but it was withdrawn in 1992 due to a safety issue in which the balloon could rupture and block patients' arteries. "The new device aims to address the design failings of the earlier device," said...

  • DES MOINES, Iowa— The U.S. government expects to spend $191 million to pay chicken and turkey farmers for birds lost to avian flu, Agriculture Secretary Tom Vilsack said Tuesday as he called for Congress to consider a disaster program for poultry producers similar to that for other livestock farmers. Iowa, Minnesota and Missouri lost the most birds.

  • LONDON, July 28- Researchers in the United States trying to develop a vaccine against the deadly Middle East Respiratory Syndrome virus say they have had early signs of success in animal experiments. MERS, which causes coughing and fever and can lead to fatal pneumonia and kidney failure, has been reported mainly in Saudi Arabia and South Korea but has also been...

  • SAN FRANCISCO— Jody Kearns doesn't like to spend time obsessing about her Parkinson's disease. The 56- year-old dietitian from Syracuse, New York, had to give up bicycling because the disorder affected her balance. More than 75,000 people have enrolled in health studies that use specialized iPhone apps, built with software Apple Inc. developed to help turn the...

  • UPDATE 1-Bellerophon's heart device fails study Monday, 27 Jul 2015 | 7:31 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was licensed to Bellerophon by BioLineRx Ltd in 2009.. BioLineRx's U.S.-listed shares fell 18 percent to $1.76 in premarket...

  • Bellerophon's heart device fails study Monday, 27 Jul 2015 | 6:36 AM ET

    July 27- Bellerophon Therapeutics Inc said its implantable heart device failed to prevent heart failure in patients in a large study, casting doubts over an approval for the device in Europe. The device, Bioabsorbable Cardiac Matrix, was tested in 303 patients who had already suffered a heart attack. The device was licensed to Bellerophon by BioLineRx Ltd in...

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • WASHINGTON, July 24- The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a hereditary form of the condition and those with cardiovascular disease. The FDA ruling came just hours after European regulators recommended...

  • WASHINGTON— The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. The drug from Sanofi and Regeneron Pharmaceuticals Inc. offers an important new option for millions of patients at high risk of heart disease. But the drug's sky-high...

  • He lost half of a year's normal production and income and won't be able to sell turkeys for months, but the central Minnesota farmer feels good to be getting back to normal. A USDA update Friday said scientists still haven't nailed down the specific ways the virus spreads from the wild into barns but research is continuing in Iowa, Nebraska, Minnesota, the Dakotas...

  • July 24- The U.S. Food and Drug Administration approved Novartis AG's oral pill to treat the most common form of advanced skin cancer. Roche Holding AG's Erivedge was the first pill to be approved in 2012 by the FDA for the condition. One in five Americans are likely to develop skin cancer in their lifetime, according to the American Academy of Dermatology.

  • July 24- The U.S. Food and Drug Administration approved AbbVie Inc's treatment that targets hepatitis C virus with the rarest genotype, or genetic makeup. The three drugs included in Technivie are also in Viekira Pak, AbbVie's treatment for genotype 1 hep C virus infection. Separately, AbbVie reported lower-than-expected revenue for the first time in six...

  • Abbvie gets U.S. FDA approval for Hep C drug Friday, 24 Jul 2015 | 11:42 AM ET

    July 24- The U.S. Food and Drug Administration approved Abbvie Inc's treatment that targets the most common genotype, or genetic makeup, of hepatitis C virus. The drug, Technivie, was approved for the treatment of hepatitis C virus genotype 4 infections, the regulator said on Friday. The drug is approved for use in combination with the compound, ribavirin, for the...

  • How effective is new malaria vaccine? Friday, 24 Jul 2015 | 11:40 AM ET
    How effective is new malaria vaccine?

    Suki Virji, analyst for Scrip Intelligence, discusses the malaria vaccine developed by GlaxoSmithKline, which has received a "green light" by the European Medicines Agency.

  • LONDON, July 24- AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. FKB-- itself a tie-up between Fujifilm and Kyowa Hakko Kirin-- commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in...

  • *Sanofi/ Regeneron PCSK9 drug Praluent endorsed by EMA. *Praluent to compete with Amgen's rival product Repatha. LONDON, July 24- A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.

  • July 24- Sales of Biogen Inc's roster of multiple sclerosis drugs failed to meet analysts' expectation, prompting the company to slash its full-year profit and sales forecast. Tecfidera's sales were $833 million in the second quarter ended June 30, well below Wall Street's estimate of about $933 million, according to Evercore ISI. Sales of Biogen's injectable...